Do cyclosporin profiles provide useful information in the management of renal transplant recipients?

Nephrology Dialysis Transplantation

Volumn 11, Issue 8, 1996, Pages 1597-1602

  Bowles, M J ^a,b   Waters, J B ^a   Lechler, R I ^a   Williams, G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Cyclosporin A; Nephrotoxicity; Pharmacokinetic profiles; Rejection; Renal transplantation

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0029934002     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.8.1597     Document Type: Article

References (27)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738
2. Lindholm A. Therapeutic monitoring of cyclosporin - an update. Eur J Clin Pharmacol 1991; 41: 273-283
3. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-644
4. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465-477
5. Savoldi S, Kahan BD. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. Transplant Proc 1986; 18 [Suppl. 5]: 120 128
6. Kahan BD. Immunosuppressive therapy. Curr Opin Immunol 1992; 4: 553-560
7. Tett S, Espinos E, Weekes L. Who is ordering all those cyclosporin concentrations and how do they use them? An audit of cyclosporin therapeutic drug monitoring. Ther Drug Monit 1993; 15: 195 198
8. Grevel J. Significance of cyclosporine pharmacokinetics. Transplant Proc 1988; 20 [Suppl 2]: 428-434
9. Phillips TM, Karmi SA, Frantz SC. Henriques HF. Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: A pharmacokinetic study. Transplant Proc 1988; 20 [Suppl 2]: 457-461
10. Johnston A, Sketris I, Marsden JT et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990; 22: 1345-1346
11. Lindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993; 55: 985-993
12. Kahan BD, Welsh M, Rutzky L et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992; 53: 345-351
13. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graftversus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65-70
14. Holt DW, Marsden JT, Johnston A, Bewiek M, Taube DH. Blood cyclosporin concentrations and renal allograft dysfunction. Br Med 1986; 293: 1057-1059
15. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218
16. Granger DK, Amin NB, Sorenson AL, Gillingham KJ, Canafax DM, Matas AJ. Cyclosporin levels impact early rejection episodes. Transplant Proc 1994; 26: 2513
17. Henry ML, Bowers VD, Fanning WJ, Sommer BG, Ferguson RM. Cyclosporine levels are not helpful. Transplant Proc 1988; 20 [Suppl 2]: 419-421
18. Ubhi CS, Woodhouse L, Guillou PJ, Giles GR. Is there a therapeutic range for monitoring plasma cyclosporin in renal allograft recipients? Nephrol Dial Transplant 1988; 3: 814-819
19. Keown PA. Optimizing cyclosporine therapy: dose, levels, and monitoring. Transplant Proc 1988; 20 [Suppl 2]: 382-389
20. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246-248
21. Keown PA, Ulan RA, Wall WJ et al. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet 1981; 686-689
22. Peters AM, Heckmatt JZ, Hasson N et al. Renal haemodynamics of cyclosporin A nephrotoxicity in children with juvenile dermatomyositis. Clin Sci 1991; 81: 153-159
23. McNally PG, Feehally J. Pathophysiology of cyclosporin A nephrotoxicity. experimental and clinical observations. Nephrol Dial Transplant 1992; 7: 791-804
24. Rajaseker MR, Lodge JPA, Irving HC, Giles GR. Early computed colour echo Doppler imaging following renal transplantation. Br J Surg 1991; 78: 872-874
25. Carrier M, Tronc F, Stewart D, Pelletier LC. Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am J Physiol 1991; 261: H1791-H1796
26. Cantarovich F, Cantarovich D, Touraine JL et al. Cyclosporine dose adjustment in patients with normal serum creatinine and trough levels: a challenge for successful long-term treatment. Transplant Proc 1988; 20 [Suppl 2]: 402-406
27. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24(6): 472-495